Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Invites Tesaro To Put Zejula Into Cancer Drugs Fund

Executive Summary

Tesaro's PARP inhibitor for ovarian cancer has not been recommended for routine use on the NHS, but NICE has suggested that the company try the Cancer Drugs Fund route. 

You may also be interested in...



UK’s NICE Xalkori Recommendation Signals Issues For Securing Market Access For Rarer Cancer Drugs

Two more drugs are set to enter England’s Cancer Drugs Fund: Tesaro’s Zejula and Pfizer’s Xalkori. Recommendations on the latter highlight difficulties for rarer cancer treatments.

Roche's Atezolizumab Gets CDF Place For Bladder Cancer

Roche may have stolen a march on other checkpoint inhibitors in Europe's bladder cancer market by gaining a Cancer Drugs Fund place for Tecentriq in final draft guidance from England's health technology assessment body, NICE.

Novartis CEO Touts R&D 'Wild Cards' As Proof Of Deep Pipeline

Potentially transformative treatments for severe asthma, COPD and osteoarthritis are among some of the below-the-radar projects the Swiss major is advancing, according to Vas Narasimhan. 

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel